Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

French (CAC) Pharma Industry Analysis

UpdatedDec 13, 2025
DataAggregated Company Financials
Companies6
  • 7D-1.9%
  • 3M3.1%
  • 1Y-4.8%
  • YTD-9.7%

Over the last 7 days, the Pharma industry has dropped 1.1%, driven by a pullback from Sanofi of 1.1%. In contrast, MedinCell has gained 13%. Overall the industry is down 5.9% in 12 months. As for the next few years, earnings are expected to grow by 12% per annum.

Industry Valuation and Performance

Has the French Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 13 Dec 2025€115.9b€53.0b€7.0b21.3x16.6x2.2x
Mon, 10 Nov 2025€118.6b€53.0b€7.0b21.7x17x2.2x
Wed, 08 Oct 2025€117.1b€52.9b€6.9b19.7x16.9x2.2x
Fri, 05 Sep 2025€110.4b€52.8b€6.9b18.8x16x2.1x
Sun, 03 Aug 2025€110.9b€52.8b€6.9b19x16x2.1x
Tue, 01 Jul 2025€112.7b€52.1b€6.7b18.4x16.9x2.2x
Thu, 29 May 2025€125.7b€52.1b€6.7b18.6x18.9x2.4x
Sat, 26 Apr 2025€125.2b€52.1b€6.7b18.2x18.8x2.4x
Mon, 24 Mar 2025€146.0b€51.2b€5.9b17.6x24.5x2.9x
Wed, 19 Feb 2025€143.3b€51.2b€5.8b18.4x24.8x2.8x
Fri, 17 Jan 2025€136.6b€55.2b€5.1b18.4x26.8x2.5x
Sun, 15 Dec 2024€125.1b€55.2b€5.1b19.5x24.5x2.3x
Tue, 12 Nov 2024€134.0b€55.2b€5.1b20.9x26.3x2.4x
Thu, 10 Oct 2024€141.3b€53.8b€4.8b22.7x29.4x2.6x
Sat, 07 Sep 2024€144.9b€53.8b€4.8b19.5x30.2x2.7x
Mon, 05 Aug 2024€134.0b€53.8b€4.8b21x27.9x2.5x
Wed, 03 Jul 2024€129.0b€52.9b€5.2b20x25x2.4x
Fri, 31 May 2024€125.7b€52.9b€5.2b21.6x24.3x2.4x
Sun, 28 Apr 2024€128.2b€52.9b€5.2b21.2x24.7x2.4x
Tue, 26 Mar 2024€125.9b€52.7b€6.0b20.7x20.8x2.4x
Thu, 22 Feb 2024€123.5b€53.0b€6.3b20.2x19.7x2.3x
Sat, 20 Jan 2024€132.0b€52.2b€9.7b19.6x13.6x2.5x
Mon, 18 Dec 2023€123.5b€52.2b€9.7b16.9x12.7x2.4x
Wed, 15 Nov 2023€119.5b€52.2b€9.7b17.3x12.3x2.3x
Fri, 13 Oct 2023€145.1b€52.6b€9.3b18.2x15.6x2.8x
Sun, 10 Sep 2023€141.0b€52.6b€9.3b20.8x15.2x2.7x
Tue, 08 Aug 2023€133.1b€52.6b€9.3b21.2x14.4x2.5x
Thu, 06 Jul 2023€136.6b€52.6b€9.1b17.6x14.9x2.6x
Sat, 03 Jun 2023€133.0b€52.6b€9.1b15.4x14.5x2.5x
Mon, 01 May 2023€139.4b€52.6b€9.1b15.5x15.2x2.6x
Wed, 29 Mar 2023€138.4b€51.8b€9.2b15.6x15.1x2.7x
Fri, 24 Feb 2023€127.0b€51.7b€7.5b18.4x16.9x2.5x
Sun, 22 Jan 2023€127.0b€50.7b€7.4b18.4x17.3x2.5x
Tue, 20 Dec 2022€124.4b€50.7b€7.4b16.6x16.9x2.5x
Price to Earnings Ratio

16.9x


Total Market Cap: €124.4bTotal Earnings: €7.4bTotal Revenue: €50.7bTotal Market Cap vs Earnings and Revenue0%0%0%
French Pharma Industry Price to Earnings3Y Average 19.4x202320242025
Current Industry PE
  • Investors are pessimistic on the French Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 16.7x which is lower than its 3-year average PE of 19.4x.
  • The 3-year average PS ratio of 2.5x is higher than the industry's current PS ratio of 2.2x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Trends

Which industries have driven the changes within the French Healthcare industry?

FR Market-0.57%
Healthcare-3.99%
Pharma-1.91%
Pharma-1.91%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MEDCL MedinCell€27.566.0%
+€51.6m		69.1%PS32.9x
VETO Vetoquinol€77.002.7%
+€23.6m		-1.0%PE15.1x
ALTHX THX Pharma Société Anonyme€2.2924.5%
+€6.2m		368.3%PS36.1x
EAPI Euroapi€3.071.5%
+€4.4m		3.4%PS0.3x
ALDVI Advicenne€1.814.3%
+€1.0m		6.7%PS4.4x

Latest News

MEDCL
€27.56
MedinCell
7D
6.0%
1Y
69.1%
SAN
€83.32
Sanofi
7D
-2.0%
1Y
-6.6%

SAN: Future Returns Will Depend On Execution Of Late-Stage Pipeline

Analysts have nudged their fair value estimate for Sanofi slightly lower from EUR 106.26 to about EUR 105.20, citing marginally softer revenue growth assumptions, partially offset by a modestly stronger profit margin outlook and a slightly reduced forward P E multiple. Analyst Commentary Analyst sentiment on Sanofi remains broadly constructive, with recent fair value adjustments reflecting a more nuanced balance between growth ambitions and execution risks.
VIRP
€339.00
Virbac
7D
-4.9%
1Y
5.1%

VIRP: Broad Regional Momentum Will Support Upgraded Buy Rating Through 2025

Analysts have raised their price target on Virbac by EUR 25 to EUR 415, citing an acceleration in the company’s growth across all regions. Analyst Commentary Following the recent upgrade, research coverage has focused on the sustainability of Virbac’s growth acceleration and its implications for valuation.
IPN
€121.10
Ipsen
7D
-0.7%
1Y
11.8%

IPN: Guidance Upgrade And Competition Concerns Will Shape Balanced Future Outlook

Analysts have trimmed their price target on Ipsen by approximately EUR 1 to around EUR 130, reflecting slightly lower long term growth and margin expectations amid rising competitive pressure on key drug Somatuline. Analyst Commentary Analyst sentiment around Ipsen has turned more cautious, with recent revisions reflecting heightened concern about the sustainability of growth in key endocrine oncology franchises and the implications for valuation.
BOI
€29.15
Boiron
7D
-5.2%
1Y
9.0%

Is Boiron (EPA:BOI) Using Too Much Debt?

Dec 05
Is Boiron (EPA:BOI) Using Too Much Debt?
ALTHX
€2.29
THX Pharma Société Anonyme
7D
24.5%
1Y
368.3%
EAPI
€3.07
Euroapi
7D
1.5%
1Y
3.4%
MLCOT
€0.12
Reboost Blockchain
7D
-11.8%
1Y
1,100.0%
ALDVI
€1.81
Advicenne
7D
4.3%
1Y
6.7%
AB
€1.22
AB Science
7D
0.3%
1Y
33.6%
VETO
€77.00
Vetoquinol
7D
2.7%
1Y
-1.0%